PARP is a therapeutic target, and PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) have been approved for the treatment of prostate, ovarian, breast and pancreatic cancer, targeting a synthetic lethal effect between PARP inhibition and deficiencies in homologous recombination (149,150). Here, PARP1 is linked to familial pancreatic carcinoma.